Search

Your search keyword '"Drew Deniger"' showing total 9 results
Start Over Author "Drew Deniger"
9 results on '"Drew Deniger"'

1. 226 Neoantigen-specific TCR-T cells targeting shared hotspot mutations for adoptive cell therapy in common epithelial cancers

Author

David Torres, Yaoyao Shi, Drew Deniger, Thomas Hunt, Ana Korngold, Lin-Kin Yong, Ugochi Ibekwe, Julissa Simmons, Phillip Eckels, Elizabeth Figueroa, Michelle Hotard, Frances Adeyemi, Tegan Markus, Lenka Hurton, Matthew Collinson-Pautz, Priya Balasubramanian, Cathy Wang, Jourdan Andersson, Lauren Heese, Mariam Khalil, Emarco Olivares, Geraldine Bardelli, Kelly O’Brien, Haroon Hashmi, Alena Chekmasova, Raffaele Baffa, Tom Spencer, and Eleanor De Groot

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2021
Full Text
View/download PDF

2. 333 Targeting the apical intracellular checkpoint CISH unleashes T cell neoantigen reactivity and effector program

Author

Matthew Johnson, Ying Hu, Nicholas Restifo, Jared Gartner, Douglas Palmer, Shashank Patel, Maria Parkhurst, Todd Prickett, Parisa Malekzadeh, David McKenna, Zulmarie Franco, Suman Vodnala, Beau Webber, Yogin Patel, Christine Kariya, Walker Lahr, Rigel Kishton, Devikala Gurusamy, Miechaleen Diers, Natalie Wolf, Nicholas Slipek, Darin Sumstad, Lydia Viney, Tom Henley, Tilmann Bürckstümmer, Oliver Baker, Chunhua Yan, Daoud Meerzaman, Kartik Padhan, Winnie Lo, Li Jia, Drew Deniger, R Scott McIvor, Modassir Choudhry, and Branden Moriarity

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2020
Full Text
View/download PDF

3. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.

Author

Radhika Thokala, Simon Olivares, Tiejuan Mi, Sourindra Maiti, Drew Deniger, Helen Huls, Hiroki Torikai, Harjeet Singh, Richard E Champlin, Tamara Laskowski, George McNamara, and Laurence J N Cooper

Subjects
Medicine, Science
Abstract

Adoptive immunotherapy infusing T cells with engineered specificity for CD19 expressed on B- cell malignancies is generating enthusiasm to extend this approach to other hematological malignancies, such as acute myelogenous leukemia (AML). CD123, or interleukin 3 receptor alpha, is overexpressed on most AML and some lymphoid malignancies, such as acute lymphocytic leukemia (ALL), and has been an effective target for T cells expressing chimeric antigen receptors (CARs). The prototypical CAR encodes a VH and VL from one monoclonal antibody (mAb), coupled to a transmembrane domain and one or more cytoplasmic signaling domains. Previous studies showed that treatment of an experimental AML model with CD123-specific CAR T cells was therapeutic, but at the cost of impaired myelopoiesis, highlighting the need for systems to define the antigen threshold for CAR recognition. Here, we show that CARs can be engineered using VH and VL chains derived from different CD123-specific mAbs to generate a panel of CAR+ T cells. While all CARs exhibited specificity to CD123, one VH and VL combination had reduced lysis of normal hematopoietic stem cells. This CAR's in vivo anti-tumor activity was similar whether signaling occurred via chimeric CD28 or CD137, prolonging survival in both AML and ALL models. Co-expression of inducible caspase 9 eliminated CAR+ T cells. These data help support the use of CD123-specific CARs for treatment of CD123+ hematologic malignancies.

Published
2016
Full Text
View/download PDF

5. Supplementary Tables 1 and 2 from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer

Author

Steven A. Rosenberg, David S. Schrump, Isaac Kriley, Biman C. Paria, Scott Kivitz, Satyajit Ray, Todd Prickett, Thomas E. Shelton, Parisa Malekzadeh, Drew Deniger, Anna Pasetto, Jared J. Gartner, Li Jia, Yong-Chen Lu, Eric Tran, Paul F. Robbins, Maria Parkhurst, and Winifred Lo

Abstract

Supplementary Tables 1 and 2

Published
2023
Full Text
View/download PDF

7. Data from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer

Author

Steven A. Rosenberg, David S. Schrump, Isaac Kriley, Biman C. Paria, Scott Kivitz, Satyajit Ray, Todd Prickett, Thomas E. Shelton, Parisa Malekzadeh, Drew Deniger, Anna Pasetto, Jared J. Gartner, Li Jia, Yong-Chen Lu, Eric Tran, Paul F. Robbins, Maria Parkhurst, and Winifred Lo

Abstract

Adoptive cell therapy (ACT) with T cells targeting neoantigens can mediate durable responses in patients with metastatic cancer. Cell therapies targeting common shared antigens for epithelial cancers are not yet broadly available. Here, we report the identification and characterization in one patient of T-cell receptors (TCRs) recognizing mutated p53 p.R175H, which is shared among a subset of patients with cancer. Tumor-infiltrating lymphocytes were screened for recognition of mutated neoantigens in a patient with metastatic colorectal cancer. HLA-A*0201–restricted recognition of mutated p53 p.R175H was identified, and the minimal peptide epitope was HMTEVVRHC. Reactive T cells were isolated by tetramer sorting, and three TCRs were identified. These TCRs mediated recognition of commercially available ovarian cancer, uterine carcinoma, and myeloma cell lines, as well as an NIH patient–derived esophageal adenocarcinoma line that endogenously expressed p53 p.R175H and HLA-A*0201. They also mediated recognition of p53 p.R175H+ colon, breast, and leukemia cell lines after transduction with a retrovirus encoding HLA-A*0201. This work demonstrates that common shared mutated epitopes such as those found in p53 can elicit immunogenic responses and that the application of ACT may be extended to patients with any cancer histology that expresses both HLA-A*0201 and the p53 p.R175H mutation.

Published
2023
Full Text
View/download PDF

8. Supplementary Figures from Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer

Author

Steven A. Rosenberg, David S. Schrump, Isaac Kriley, Biman C. Paria, Scott Kivitz, Satyajit Ray, Todd Prickett, Thomas E. Shelton, Parisa Malekzadeh, Drew Deniger, Anna Pasetto, Jared J. Gartner, Li Jia, Yong-Chen Lu, Eric Tran, Paul F. Robbins, Maria Parkhurst, and Winifred Lo

Abstract

Supplementary Figures 1, 2, 3, 4, 6 and 7

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results